Form 4: Avenue Therapeutics CEO MacLean Receives 170,000 Restricted Stock Units
SEC Form 4 Filing
A Form 4 filing reveals that Avenue Therapeutics CEO Alexandra MacLean was granted 170,000 restricted stock units.
Summary
- Alexandra MacLean, CEO of Avenue Therapeutics, received 170,000 restricted stock units on September 23, 2024.
- These units will vest in equal installments on September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026.
- The shares underlying the restricted stock units will be settled in the form of Avenue Therapeutics common stock.
- Settlement will occur on the earlier of the tenth business day of January following certain terminations of service or a Change in Control event.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The grant of restricted stock units is a standard practice and suggests confidence in the CEO's leadership and the company's future.
Positives
- The grant of restricted stock units aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The vesting of the restricted stock units is tied to continued service and potential change in control events, suggesting an expectation of ongoing leadership and potential strategic activity.
Industry Context
Executive compensation packages often include restricted stock units to incentivize performance and align management's interests with shareholder value. This grant is a typical component of executive compensation in the pharmaceutical industry.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry commonly include restricted stock units as a component of total compensation.
- The vesting schedule of these units is fairly standard, with vesting occurring over a period of several years to incentivize long-term performance.
- Comparing the size of this grant to similar companies and executive roles would require further analysis of Avenue Therapeutics' compensation strategy and peer group.
Stakeholder Impact
- Shareholders: The grant aligns the CEO's interests with shareholder value.
- Employees: The grant may boost employee morale by demonstrating confidence in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| 09/23/2024 | Date of transaction: Alexandra MacLean received 170,000 restricted stock units. |
| 09/25/2024 | Date of filing: Form 4 filing date. |
| 09/30/2024 | First vesting date for the restricted stock units. |
| 12/31/2024 | Second vesting date for the restricted stock units. |
| 09/23/2025 | Third vesting date for the restricted stock units. |
| 09/23/2026 | Final vesting date for the restricted stock units. |
Keywords
restricted stock units, Form 4, Avenue Therapeutics, ATXI, Alexandra MacLean, CEO, executive compensation, insider transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.